alexa

GET THE APP

Knowledge Of Tuberculosis (TB) And Human Immunodeficiency Virus (HIV) And Perception About Provider Initiated HIV Testing And Counseling Among TB Patients Attending Health Facilities In Harar Town, Eastern Ethiopia | 12940
ISSN: 2161-1165

Epidemiology: Open Access
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Knowledge of tuberculosis (TB) and human immunodeficiency virus (HIV) and perception about provider initiated HIV testing and counseling among TB patients attending health facilities in Harar town, Eastern Ethiopia

International Conference on Epidemiology and Evolutionary Genetics

Ayichew Seyoum

Accepted Abstracts: Epidemiol

DOI: 10.4172/2161-1165.S1.004

Abstract
N ational Engineering Research Center of Antibody Medicine (NERCAM) is a state-own not for profit institution which is located in Zhangjiang High-Tech Zone, Shanghai of China. NERCAM is committed to improving technology for large scale production of therapeutic antibodies in China. NERCAM is a unique business structure which consists of two academic institutions and three companies. This National Center will provide full technology platforms for development of therapeutic monoclonal antibodies by combining the revolutionary research technologies, processing and development pilot plants and large scale production facilities. The Center has full equipment for large scale manufacture of antibody medicine. The total capacity of mammalian cell culture bioreactors is 10,000L and will be expended to 50,000L at the end of year 2012. The center has thirteen antibody drugs in different stages of clinical trials and two of them are currently in Chinese market. The pipeline of antibody drugs developed in this center consists of three major categories, me too also called biosimilar or biogeneric, me better and novel therapeutic antibodies. These drugs cover almost of all available targets used clinically. New structure antibodies, such as bispecific and fusion as well as multivalent antibodies also are developed and will go to clinical study in the near future. From now, each year, the center will have one and two drugs into the market for sale. The several key issues regarding current status of development of therapeutic antibody medicine will be discussed during this presentation.
Biography
Ayichew Seyoum has completed his MSc. degree at the age of 30 years from Addis Ababa University, Ethiopia, Aklilu Lema Institute of Pathobiology on Tropical and infectious disease control. Currently he is offering courses for Health and Medical Sciences students who are in college of Medical and Health Sciences, advising students on different research projects, Guiding and Demonstrating students in the laboratory, involving on Quality assurance of Medical Laboratory Services, Participating in community and research activities which are problem solving. Act as Team Training Program supervisor, Giving Pre service Training on integrated diseases (TB, Malaria and HIV/AIDS) diagnostic methods which is supported by CDC- Ethiopia. He has published 2 papers in reputed journals, participating on 2 other projects under the title ? Assessment of knowledge and practices on integrated diseases prevention and control after launch of Health Extension Program among households in East Hararghe, Ethiopia? and also reviewing different research articles for BMC public health and African Journal of Microbiology.
Top